Role of STING protein in breast cancer: mechanisms and therapeutic implications


Review


doi: 10.1007/s12032-022-01908-4.

Affiliations

Item in Clipboard

Review

Yue Jiang et al.


Med Oncol.


.

Abstract

Breast cancer is one of the most frequent causes of cancer related death worldwide, and despite the significant advances in therapeutic approaches, a significant proportion of patients succumb to metastasis and tumor recurrence. Breast cancer is an immunogenic cancer, and therefore, immunotherapy is considered a major therapeutic strategy. The survival rate has been increased significantly in HER2+ breast cancers after immunotherapy by monoclonal antibodies alone, or combined with chemical anti-cancer agents. Moreover, in triple negative breast cancer (TNBC), a number of novel agents called immune checkpoint inhibitors have shown optimal efficacy. The major hindrance in cancer immunotherapy is frequent development of resistance and cancer remission. cGAS-STING pathway has a key role in anti-cancer immunity as its downstream signals especially type I interferon (IFN) acts as a link between innate and adaptive immunity. Considering the roles of type I IFN in enhancing dendritic cells activity, promoting the functions of CD8+ T cells, and protecting the effector cells against apoptosis, the induction of cGAS-STING pathway demonstrated promising therapeutic effects against breast cancer, especially in triple negative breast cancers. In this review, we discuss the latest findings and the recent advances regarding the role of cGAS-STING pathway and its activation in breast cancer.


Keywords:

Breast cancer; STING; cGAS.

References

    1. Samadzadeh S, Babazadeh M, Zarghami N, Pilehvar-Soltanahmadi Y, Mousazadeh H. An implantable smart hyperthermia nanofiber with switchable controlled and sustained drug release: Possible application in prevention of cancer local recurrence. Mater. Sci. Eng. 2021;118111384-S0928493120333026 111384. doi.org/10.1016/j.msec.2020.111384

    1. Casás-Selves M, DeGregori J. How cancer shapes evolution and how evolution shapes cancer. Evol: Educ outreach. 2011;4(4):624–34.

    1. Fouad YA, Aanei C. Revisiting the hallmarks of cancer. Am J Cancer Res. 2017;7(5):1016.



      PubMed



      PMC

    1. Sheervalilou R, Ansarin K, Fekri Aval S, Shirvaliloo S, Pilehvar-Soltanahmadi Y, Mohammadian M, Zarghami N. An update on sputum MicroRNAs in lung cancer diagnosis. Diagn. Cytopathol. 2016;44(5):442–449. doi.org/10.1002/dc.23444



      DOI



      PubMed

    1. Hassanpour SH, Dehghani M. Review of cancer from perspective of molecular. J Cancer Res Pract. 2017;4(4):127–9.



      DOI

LinkOut – more resources

  • Research Materials

  • Miscellaneous

Read more here: Source link